Back to News
Market Impact: 0.15
GRAIL To Highlight NHS-Galleri, PATHFINDER 2 Findings Amid FDA Review; Stock Up
Source: Nasdaq
Healthcare & Biotech
GRAIL plans to present additional data from the NHS-Galleri trial and PATHFINDER 2 study evaluating its Galleri multi-cancer early detection test at the Early Detection of Cancer Conference in Edinburgh, October 6–8, 2026. The provided article text contains no study results or other details about the data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
GRAL0.15
More News
- Why is Telix Pharmaceuticals stock rallying today?
- Why is Natera stock sliding today?
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
- LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
- Why is Illumina stock sliding today?